Congress Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Congress Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$206M	Sell	658,556 -1,355	-0.2%	-$401K	1.33%	8
2026 Q2	$209M	Buy	659,911 +155,274	+31%	+$36.6M	1.28%	9
2026 Q1	$101M	Buy	504,637 +24,574	+5%	+$4.86M	0.72%	41
2025 Q4	$90.8M	Sell	480,063 -187,248	-28%	-$36M	0.64%	52
2025 Q3	$118M	Buy	667,311 +19,370	+3%	+$2.88M	0.79%	41
2025 Q2	$73.7M	Buy	647,941 +5,229	+0.8%	+$559K	0.51%	84
2025 Q1	$67.6M	Buy	642,712 +21,230	+3%	+$2.4M	0.51%	78
2024 Q4	$66.6M	Buy	621,482 +17,444	+3%	+$1.97M	0.45%	87
2024 Q3	$60.5M	Buy	604,038 +17,414	+3%	+$1.75M	0.41%	93
2024 Q2	$49.4M	Buy	+586,624	New	+$46.7M	0.35%	96
2020 Q4	–	Sell	-51,897	Closed	-$3.09M	–	350
2020 Q3	$3.09M	Buy	51,897 +2,289	+5%	+$156K	0.03%	204
2020 Q2	$3.46M	Buy	49,608 +1,050	+2%	+$66.6K	0.04%	189
2020 Q1	$2.2M	Buy	48,558 +17,974	+59%	+$1.02M	0.03%	211
2019 Q4	$1.99M	Sell	30,584 -10,393	-25%	-$695K	0.02%	252
2019 Q3	$2.54M	Buy	40,977 +2,560	+7%	+$161K	0.03%	249
2019 Q2	$2.74M	Buy	38,417 +2,588	+7%	+$191K	0.03%	252
2019 Q1	$2.81M	Buy	35,829 +1,536	+4%	+$116K	0.04%	241
2018 Q4	$2.9M	Sell	34,293 -72	-0.2%	-$7.68K	0.04%	232
2018 Q3	$5.88M	Sell	34,365 -653	-2%	-$98.4K	0.08%	164
2018 Q2	$4.53M	Buy	35,018 +1,623	+5%	+$181K	0.06%	190
2018 Q1	$3.44M	Buy	33,395 +3,530	+12%	+$349K	0.05%	219
2017 Q4	$2.55M	Buy	29,865 +6,052	+25%	+$525K	0.04%	236
2017 Q3	$2.02M	Buy	23,813 +11,572	+95%	+$916K	0.03%	257
2017 Q2	$927K	Buy	12,241 +1,977	+19%	+$138K	0.02%	201
2017 Q1	$678K	Buy	10,264 +3,076	+43%	+$202K	0.01%	214
2016 Q4	$456K	Buy	+7,188	New	+$454K	0.01%	222

Other funds holding LGND

MNBTD

Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return

ACM

Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return

VAG

VisionPoint Advisory Group Dallas, Texas $636M AUM 21.4% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

RWS

Retirement Wealth Solutions Marshfield, Wisconsin $189M AUM 13.41% 1-Year Est. Return

Congress Asset Management's LGND Position: Q3 2026 in Review

Congress Asset Management reduced its Ligand Pharmaceuticals (LGND) stake by 0.21% in Q3 2026, selling an estimated $401K and leaving 658,556 shares worth $206M. The position accounts for 1.33% of the portfolio, ranked #8.

Congress Asset Management first reported a position in LGND in Q4 2016 and has held it in 26 quarters since. The position peaked at $209M in Q2 2026. 14 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

Congress Asset Management held 658,556 shares of Ligand Pharmaceuticals worth $206M as of Q3 2026.
Congress Asset Management sold 1,355 Ligand Pharmaceuticals shares in Q3 2026, an estimated $401K.
Ligand Pharmaceuticals made up 1.33% of Congress Asset Management's portfolio in Q3 2026, its #8 holding.
Congress Asset Management first reported a position in Ligand Pharmaceuticals in Q4 2016 and has held it in 26 quarters since.
Congress Asset Management's Ligand Pharmaceuticals position peaked at $209M in Q2 2026.
14 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Congress Asset Management's 13F filing for Q3 2026, filed 6 Oct 2026.